Gastroenterology 2019;■:1–10

Synthetic Neoepitopes of the Transglutaminase–Deamidated Gliadin Complex as Biomarkers for Diagnosing and Monitoring Celiac Disease

Q6 Rok Seon Choung,[1] Shahryar Khaleghi Rostamkolaei,[1] Josephine M. Ju,[1] Eric V. Marietta,[1] Carol T. Van Dyke,[1] J. J. Rajasekaran,[2] Vasanth Jayaraman,[2] Tianhao Wang,[2] Kang Bei,[2] Karenah E. Rajasekaran,[2] Karthik Krishna,[2] Hari Krishnan Krishnamurthy,[2] and Joseph A. Murray[1]

[1]Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota; and [2]Vibrant Sciences LLC, San Carlos, California



Tests	Sensitivity % (95% CI)	Specificity % (95% CI)	Overall Accuracy % (95% CI)	PPV	NPV
tTG-DGP complex	84 (74-90)	95 (88-98)	90 (84-94)	0.94	0.86
tTG-IgA	27 (19-38)	93 (85-97)	61 (53-68)	0.78	0.57
DGP-IgA	48 (38-59)	91 (83–95)	70 (63–76)	0.83	0.64

BACKGROUND & AIMS: Celiac disease (CeD) has characteristics of an autoimmune disease, such as increased antibody levels to tissue transglutaminase (tTG). However, assays to measure these biomarkers in blood samples do not identify patients with sufficient accuracy for diagnosis or monitoring of CeD. We aimed to discover biomarkers of CeD derived from neoepitopes of deamidated gliadin peptides (DGP) and tTG fragments and to determine if immune reactivity against these epitopes can identify patients with CeD with mucosal healing. **METHODS:** We analyzed serum samples from 90 patients with biopsy-proven CeD and 79 healthy individuals (controls) for immune reactivity against the tTG-DGP complex (discovery cohort). A fluorescent peptide microarray platform was used to estimate the antibody-binding intensity of each synthesized tTG-DGP epitope. We validated out findings in 82 patients with newly diagnosed CeD and 217 controls. We tested the ability of our peptide panel to identify patients with mucosal healing (based on the histologic analysis) using serum samples from patients with treated and healed CeD (n = 85), patients with treated but unhealed CeD (n = 81; villous atrophy despite a adhering a gluten-free diet), patients with untreated CeD (n = 82) and disease controls (n = 27), villous atrophy without CeD), and healthy controls (n = 217). Data were analyzed using principal component analysis followed by machine learning and support vector machine modeling. **RESULTS:** We identified 172 immunogenic epitopes of the tTG-DGP complex. We found significantly increased immune reactivity against these epitopes vs controls. In the training cohort, the set of neoepitopes derived from the tTG-DGP complex identified patients with CeD with 99% sensitivity and 100% specificity. Serum samples from patients with untreated CeD had the greatest mean antibody-binding intensity against the tTG-DGP complex (32.5 ± 16.4). The average antibody-binding intensity was significantly higher in serum from patients with treated but unhealed CeD mucosa (15.1 ± 7.5) than in patients with treated and healed CeD mucosa (5.5 ± 3.4) ($P < .001$). The assay identified patients with mucosa healing status with 84% sensitivity and 95% specificity. **CONCLUSIONS:** We identified immunogenic epitopes of the tTG-DGP complex, and found that an assay to measure the immune response to epitopes accurately identified patients with CeD, as well as patients with mucosal healing. This biomarker assay might be used in detection and monitoring of patients with CeD.

Keywords: Noninvasive Marker; Diagnostic; Follow-up; Response to Treatment.

CLINICAL AT

UNCORRECTED PROOF

ARTICLE IN PRESS

WHAT YOU NEED TO KNOW

BACKGROUND AND CONTEXT

Placeholder text • Placeholder text • Placeholder text • Placeholder text • Placeholder text • Placeholder text • Placeholder text • Placeholder text • Placeholder text • Placeholder text •

NEW FINDINGS

Placeholder text • Placeholder text • Placeholder text • Placeholder text • Placeholder text • Placeholder text • Placeholder text • Placeholder text • Placeholder text • Placeholder text •

LIMITATIONS

Placeholder text • Placeholder text • Placeholder text • Placeholder text • Placeholder text • Placeholder text • Placeholder text • Placeholder text • Placeholder text • Placeholder text •

IMPACT

Placeholder text • Placeholder text • Placeholder text • Placeholder text • Placeholder text • Placeholder text • Placeholder text • Placeholder text • Placeholder text • Placeholder text •

Celiac disease (CeD) has the features of an autoimmune disease, such as increased antibody levels to the self-antigen tissue transglutaminase (tTG) that return to normal when adhering to a gluten-free diet (GFD).[1] The adaptive response of CeD consists of T-cell– and B-cell–mediated responses to gliadins and similar proteins in wheat, barley, and rye.[2,3] Currently, the primary serologic markers of CeD are antibodies to tTG and gliadin peptides (GPs) that have been deamidated by tTG.[4,5] Autoimmunity (characterized by anti-tTG antibodies) is uniquely dependent on the continued ingestion of gluten.[6–8] Several studies showed that deamidated gliadin-derived peptides (DGPs) that have been modified by tTG are more immunogenic in patients with CeD than native GPs, which have not been modified by tTG.[9,10] Furthermore, Sollid et al.[11] proposed the hapten-carrier theory to explain autoimmunity initiation in patients with CeD. Compatible with this theory, a complex consisting of small parts of DGPs and tTG may elicit or augment an immune response in CeD. Furthermore, neo-epitopes from the tTG-DGP complex were suggested as accurate diagnostic markers of CeD.[12,13] However, this association between tTG and DGPs has not been fully established.

Serologic tests have shown high sensitivity and specificity for diagnosing untreated CeD, especially tests for tTG–immunoglobulin A (tTG-IgA), but less so for DGP-IgA and DGP–immunoglobulin G, but upper endoscopy with biopsy of the duodenum is required to confirm diagnosis because of variability in CeD serology.[1] Moreover, a reference tTG-IgA level after starting a GFD is a poor predictor of intestinal healing.[14] The only accurate method for verifying intestinal healing is to histologically evaluate a biopsy of the duodenum, which is invasive and expensive. Previously, we developed an ultrahigh-density protein and peptide array that enables comprehensive interrogation of the antibody responses to native peptides, DGPs, and tTG.[3] Thus, in this study we aimed to explore epitope recognition in serum samples from patients with untreated CeD, in particular immune recognition of novel combinations of tTG and DGPs, and to further determine whether the antibody recognition patterns of these peptides are predictive of mucosal healing in patients with treated CeD.

Methods

This analysis is composed of 2 case-control studies. The first study aimed to identify a potential biomarker derived from novel combinations of tTG and DGPs for diagnosing CeD. The second study further evaluated the biomarker identified in the first study to differentiate healing status in patients with CeD who were adhering to a GFD. Our study was approved by the Institutional Review Board of Mayo Clinic in Rochester, Minnesota.

Study Population

Cohorts for identifying diagnostic markers (Supplementary Tables 1 and 2). To discover potential biomarkers for CeD, 90 patients with biopsy-proven CeD and 79 healthy control patients comprised the exploratory population, from which serum samples were collected in our previous study.[3] Another cohort of 82 patients with newly diagnosed CeD and 217 control patients whose serum samples were prospectively collected was used as the validation cohort to verify the diagnostic utility of the biomarker discovered in the first exploratory cohort. Among 82 patients with newly diagnosed CeD in the validation set, 4 patients with IgA deficiency were included.

Cohorts for disease monitoring. To evaluate the identified biomarker for predicting mucosal healing status in patients with treated CeD, serum samples were prospectively collected from patients with treated and healed CeD mucosa ($n = 85$), patients with treated but unhealed CeD mucosa ($n = 81$), patients with untreated CeD mucosa ($n = 82$), and control patients ($n = 217$). Mucosal healing status was defined by persistent villous atrophy despite adhering to a GFD or histologic recovery (no villous atrophy). Patients with refractory CeD were not included in this study. The mucosal healing status in the small intestine was classified based on the pathologic reports; treated patients with CeD who had partial or total villous atrophy were categorized into treated but unhealed CeD group.

Controls with villous atrophy but no CeD (disease controls). To compare the immune reactivity against epitopes of DGP, tTG, and tTG-DGP complex, we also tested serum samples of selected disease controls who were diagnosed with autoimmune enteropathy ($n = 10$), common variable immune

Abbreviations used in this paper: CeD, celiac disease; DGP, deamidated gliadin-derived peptide; Fmoc, fluorenylmethoxycarbonyl; GFD, gluten-free diet; GP, gliadin peptide; IgA, immunoglobulin A; ROC, receiver operating characteristic; tTG, tissue transglutaminase.

© 2018 by the AGA Institute
0016-5085/$36.00
https://doi.org/10.1053/j.gastro.2018.10.025

ARTICLE IN PRESS

deficiency associated enteropathy (n = 6), or drug-induced spruelike enteropathy (n = 11).

Peptide Synthesis

The peptide array was described in our previous study.[3] Briefly, for solid-phase peptide synthesis, silicon-based wafers (300-mm diameter), with a 100-nm-tall, thermal oxide–coated feature area and nonfeature area containing silicon, were made using photolithography and an inductively coupled plasma deep-etching technique. The surface of the prepared silicon-based wafer contained a monolayer of aminosilane that provided peptide attachment sites, in which peptide synthesis was performed using standard fluorenylmethoxycarbonyl (Fmoc) chemistry. After Fmoc protection was removed, the unprotected amine was coupled with the incoming desired Fmoc amino acid using a specific reticle that activates only the desired site where the incoming amino acid needs to be coupled. The process was repeated for each individual layer of amino acids to create the desired peptide sequences at each feature area.

tTG and the tTG-DGP Complex

In the previous study,[3] 12-mer peptides, with sequences from a lateral shift of 2 amino acids in α, β, γ, and Ω fractions of gliadin, were synthesized on silicon-based wafers. In addition, in these synthetic GPs, each glutamic acid was replaced in the position of glutamine, mimicking the deamidation of GPs (DGPs). The peptide microarray immunoassay was used to assess native peptides, DGPs, and key 3-mer GP sequences with high antibody-binding intensity associated with CeD.[3] Similar to GPs, overlapping 12-mer peptides and various lengths of tTG were synthesized. For the main purpose of this study, novel combined sequences, which were combinations of key 3-mer GP sequences and tTG subsequences, were synthesized on the silicon-based wafers. For example, in the new combined sequence YGDGVS**QPEQPF**, YGDGVS is from tTG (positions 245–250) and **QPE** and **QPF** are key 3-mer GP sequences. The basic method for selecting the new combined tTG-DGP sequences is shown in Figure 1.

Statistical Analysis

A fluorescent peptide microarray platform (Vibrant Sciences, San Carlos, CA) was used to estimate the antibody-binding intensity of each synthesized tTG-DGP neoepitope. The region of interest stitching program using JAVA transformed an image file from the scan of a peptide microarray chip to individual antibody-binding intensity values, which were calculated using the median foreground intensity and then applying binary log transformation to stabilize variance. Each antibody-binding intensity value is linked to a corresponding peptide sequence. A random forest was used to remove the unreliable peptide sequences of the tTG-DGP complex.[15] A random forest classifier was trained to detect areas of peptide sequences with values that were not within the 95% linear regression confidence band of a single linear regression analysis of multiple assays (performed using the rapmad [Robust Analysis of Peptide MicroArray Data] R-package).[16] Furthermore, background normalization modeling was also applied, which was performed using an expectation-maximization algorithm (performed using R-package) that placed blank spots where no sequences were synthesized. After eliminating background noise and unreliable peptide sequences, support vector machine modeling[17] was applied to the training set to construct a hyperplane and maximize the margins of the training data between the 2 classes (CeD vs no CeD) (performed using the Python package), with the aim of identifying the disease-associated peptide sequences of the tTG-DGP complex. Based on results of the support vector machine training, the identified disease-associated peptide sequences were then tested on unknown samples to compute the prediction accuracy, sensitivity, and specificity. Further receiver operating characteristic (ROC) curve analysis was performed to determine the sensitivity and specificity of each peptide. The threshold value for the ROC curve of each peptide was determined by choosing the value with the highest sensitivity and specificity. Furthermore, principal component analysis, hierarchical cluster analysis with heat maps, and random forest multivariate analysis were performed using the R or Python package.[18]

Results

Diagnostic Accuracy of the tTG-DGP Complex

The synthesized tTG peptide fragments were tested in serum samples obtained from 90 patients with CeD and 79 control patients to determine immune reactivity against tTG fragments. Interestingly, immune reactivity against the tTG fragments was not significantly increased in patients with



Figure 1. Combined epitopes of the tTG-DGP complex. Examples of 3 different ways to combine tTG and GP segments. YGDGVS is located at positions 245 to 250 of the tTG peptide, and PEQ and PEP are 2 key 3-mer amino acids of gliadin. *Upper row*, YGDGVS is followed by PEQ and PEP. *Middle row*, YGDGVS is located between PEQ and PEP. *Lower row*, PEQ and PEQP are followed by YGDGVS. E indicates glutamic acid; Q, glutamine; Y, Tyrosine; D, Aspartate; G, Glycine; V, Valine; P, Proline; F, Phenylalanine; S, Serine.

ARTICLE IN PRESS



Figure 2. Heat maps showing immune reactivity against tTG and the tTG-DGP. (*A*) Immune reactivity against the tTG peptide. No significant differences in immune reactivity were found between the serum samples from patients with CeD and control patients. (*B*) Immune reactivity against the neoepitopes of the tTG-DGP complex. The antibody-binding intensity of the neoepitopes of the tTG-DGP complex was significantly increased in the serum samples of the patients with celiac disease, but immune reactivity was minimal or nearly 0 in controls.

CeD compared with control patients (Figure 2*A*). Because GPs can form complexes with tTG in the duodenal mucosa of patients with CeD,[19] it is plausible that an adaptive immune response against the tTG-DGP complex would be generated. Thus, we synthesized 12-mer neoepitopes derived from tTG and key 3-mer motifs of native peptides or DGPs. These neoepitopes were tested in the serum samples of patients with CeD and control patients to identify immunogenic epitopes, which were defined as any sequence with an area under the ROC curve value >0.7. Finally, a total of 172 immunogenic epitopes of the tTG-DGP complex were identified (Supplementary Table 3). Figure 2*B* shows significantly increased immune reactivity against the neoepitopes of the tTG-DGP complex in patients with CeD compared with control patients. In the training cohort, the identified set of neoepitopes derived from the tTG-DGP complex showed very high sensitivity (99%) and specificity (100%) for diagnosing CeD. To validate the discriminative power of this tTG-DGP complex set, serum samples from a validation cohort of 82 patients with CeD and 217 control patients were assayed in a blind test. Encouragingly, this tTG-DGP complex set showed high accuracy for distinguishing CeD cases from controls, achieving 99% sensitivity and 100% specificity. In particular, compared with current serologic tests for CeD, including tTG-IgA and DGP-IgA, sensitivity and specificity were higher when using these neoepitopes to differentiate CeD cases from controls (Table 1). Serum samples from patients diagnosed with selected control diseases in which enteropathy is present in the absence of CeD, also were tested. The control disease patients consisted of 10 patients with autoimmune enteropathy, 6 patients with common variable immunodeficiency–associated enteropathy, and 11 patients with drug-induced enteropathy. We found that the immune reactivity against neoepitopes of tTG-DGP complex in these disease controls was significantly lower than in patients with CeD and was similar to other control patients. Of interest was that 4 patients with CeD with complete IgA deficiency had no immune reactivity against neoepitopes of tTG-DGP complex.

tTG-DGP Complex and Disease Activity in Patients With Treated CeD Mucosa

Table 2 shows the characteristics of treated patients with CeD according to mucosal healing status. Patients with treated and healed CeD mucosa were younger on average than patients with treated but unhealed CeD mucosa, but similar with regard to sex (73% vs 72% of patients were

Table 1. Sensitivity, Specificity, and Overall Accuracy of Using the tTG-DGP Complex to Diagnose CeD

Peptide/Protein	Sensitivity % (95% CI)	Specificity % (95% CI)	Overall Accuracy % (95% CI)	PPV	NPV
tTG-DGP complex	99 (93–100)	100 (98–100)	99 (98–100)	1	0.99
tTG-IgA[a]	90 (82–95)	99 (96–100)	97 (94–98)	0.97	0.96
DGP IgA (ELISA)[a]	91 (83–96)	97 (94–98)	97 (94–98)	0.96	0.97

ELISA, enzyme-linked immunosorbent assay; NPV, negative predictive value; PPV, positive predictive value.
[a]Determined using the tTG-IgA or DGP-IgA ELISA test (Inova Diagnostics, San Diego, CA).

CLINICAL AT
print & web 4C/FPO
UNCORRECTED PROOF

Table 2. Characteristics of the Patients With Treated CeD According to Mucosa Healing Status

Characteristic	Treated/healed CeD mucosa (n = 85)	Treated/unhealed CeD mucosa (n = 81)	*P*
Age at diagnosis, mean (SD), y	41.1 (15.2)	47.5 (15.5)	<.001
Female sex, %	73	72	.60
Duration of gluten-free diet, median (IQR), *y*	2.8 (1.7–5.1)	3.5 (1.8–8.1)	.16[a]
tTG-IgA positivity, %	7	27	<.001
DGP-IgA positivity, %	9	48	<.001
Partial or total villous atrophy, %	0	100	<.001

SD, standard deviation.
[a]Determined using nonparametric tests.

women, respectively). Interestingly, patients with treated but unhealed CeD mucosa adhered to a GFD longer than patients with treated and healed CeD, but this was not statistically significant ($P = .16$). Although 7% of patients with treated and healed CeD mucosa were positive for tTG-IgA, 27% of patients with treated but unhealed CeD mucosa were positive for tTG-IgA, and approximately three-quarters of patients with treated but unhealed CeD mucosa were negative. In addition, 48% of patients with treated but unhealed CeD mucosa were positive for DGP-IgA and 9% of patients with treated but healed CeD mucosa were positive for DGP-IgA.

Figure 3 shows immune reactivity against the neoepitopes of the tTG-DGP complex in patients with treated CeD according to healing status. Overall, as shown in the heat map, immune reactivity against the neoepitopes of the DGP-tTG complex was stronger in patients with treated but unhealed CeD mucosa than patients with treated and healed CeD mucosa and control patients (Figure 3*A*). Interestingly, the average antibody-binding intensity of the neoepitopes derived from the tTG-DGP complex significantly differed among the 5 groups ($P < .001$). Immune reactivity decreased stepwise according to intestinal mucosal damage status, showing the highest mean (standard deviation) reactivity in the patients with untreated CeD mucosa (32.5 [16.4]) followed by patients with treated but unhealed CeD mucosa (15.1 [7.5]), patients with treated and healed CeD mucosa (5.5 [3.4]), control patients (1.3 [0.5]), and disease controls (1.3 [0.4]). Furthermore, in the principal component analysis (Figure 3*B*), the patients with treated and healed CeD mucosa and control patients were closely aggregated, but the patients with treated and unhealed CeD mucosa and patients with untreated CeD mucosa were similarly distributed.

Figure 4 shows the potential utility of the neoepitopes of the tTG-DGP complex to diagnose treated but unhealed CeD mucosa compared with the tTG-IgA enzyme-linked immunosorbent assay. Although approximately 75% of patients with treated but unhealed CeD tested negative for tTG-IgA, most of these patients showed increased immune reactivity against the neoepitopes of the tTG-DGP complex. Compared with the tTG-IgA enzyme-linked immunosorbent assay, the neoepitopes of the tTG-DGP complex showed higher sensitivity (84%) and specificity (95%) with a positive predictive value of 0.94 and a negative predictive value of 0.86 for predicting healing status in patients with treated CeD mucosa (Table 3).

Discussion

Serologic tests for CeD, especially tTG-IgA tests, have high sensitivity and specificity, but biopsy of the small intestines is still considered the definitive method for diagnosing CeD. In addition, no useful noninvasive markers exist for monitoring disease activity in patients with CeD who have started a GFD. In this study, we found potential biomarkers for CeD, synthesized neoepitopes derived from DGP and tTG fragments, that show better diagnostic accuracy than current serologic tests for distinguishing patients with CeD from controls. Intriguingly, these neoepitopes showed more significant reactivity in the serum samples of the patients with treated but unhealed CeD mucosa compared with the patients with treated and healed CeD mucosa or control patients. In addition, immune reactivity against these neoepitopes was somewhat less in patients with treated but unhealed CeD mucosa than patients with untreated CeD. This distinctive increase in immune reactivity was still prominent in patients with CeD testing negative for tTG-IgA who have treated but unhealed mucosa.

Serologic tests for CeD have been extensively investigated and are considered an effective first step in diagnosing CeD.[5,20–25] Recent European guidelines suggested that sufficiently and strongly positive serologic tests for CeD, including tests for tTG-IgA and endomysial antibody, are enough to confirm CeD; therefore, biopsy of the small intestines may not be needed to diagnose CeD in this subgroup.[26] However, the results of serologic tests vary greatly across different settings and populations,[5,22,24,25] and most guidelines still recommend intestinal biopsy to reach the final diagnosis of CeD.[1,27,28] Especially the positive predictive values of CeD serologic tests are relatively low because of the low prevalence of CeD. In addition, for patients with selective IgA deficiency that is more commonly associated with CeD than in the general population, the tTG-IgA test was not effective to diagnose CeD. All 4 patients with selective IgA deficiency were negative for tTG-IgA but showed increased immune reactivity against the neoepitopes of the tTG-DGP complex. Furthermore, patients who had intestinal

UNCORRECTED PROOF

ARTICLE IN PRESS



Figure 3. Immune reactivity against epitopes of the tTG-DGP complex based on antibody-binding intensity. (*A*) Immune reactivity against epitopes of the tTG-DGP complex in patients with CeD and control patients shows higher antibody-binding intensity in patients with untreated CeD and patients with treated and unhealed CeD; but low antibody-binding intensity in patients with treated and healed CeD, healthy controls, and disease controls who had villous atrophy due to autoimmune enteropathy, common variable immunodeficiency–associated enteropathy, or drug-induced enteropathy. (*B*) Principal component analysis of immune reactivity against neoepitopes of the tTG-DGP complex. Biplot illustrates the correlation between the level of immune reactivity against the tTG-DGP complex and CeD phenotype. Treated/healed CeD group (*red dots*) and healthy controls (*blue dots*) appear together on the principal component analysis plot. In the figure, CD indicates celiac disease.

print & web 4C/FPO

villous atrophy but no CeD showed no immune reactivity against the neoepitopes of tTG-DGP complex. In the present study, the neoepitopes of the tTG-DGP complex showed comparable or even higher diagnostic accuracy for discriminating CeD than clinically available serologic tests. Indeed, several studies show that gliadin directly binds to tTG in the duodenal mucosa of patients with CeD, and the cross-linking of GPs by tTG has been suggested to be involved in the development of CeD.[12,19,29] Interestingly, we found that immune reactivity against linear epitopes of tTG was not increased in patients with CeD, suggesting that the linear epitopes of tTG may not be recognized in the sera of CeD patients. The formation of the tTG-GP complex could be an important step in the development of autoimmunity in persons with CeD, indicating epitope spread from gliadin to tTG, but the reason for the development of autoimmunity against tTG in patients with CeD is unknown.[30] In addition, few studies have tested using cross-linked tTG and GPs as biomarkers for CeD, even though diagnostic accuracy was low in these studies compared with our study.[30–32]

Although a GFD is an effective therapy for CeD, patients with CeD frequently find it difficult to adhere to a GFD, resulting in ongoing intestinal damage. Several studies have shown that persistent mucosal damage in patients with treated CeD mucosa was associated with several severe complications, including lymphoproliferative malignancy, bone diseases,[33,34] and possibly excess mortality.[35,36] Similar to other chronic conditions, disease monitoring in

ARTICLE IN PRESS



print & web 4C/FPO

Figure 4. Antibody-binding levels of tTG-IgA vs tissue transglutaminase–derived gliadin peptide complex in patients with treated but unhealed CeD. For most patients, the levels of tTG-IgA are low but the neoepitopes to tTG-DGP complex exhibit higher antibody-binding levels. Patients with high tTG-IgA, which was depicted by *red check box*, showed higher antibody-binding levels of neoepitopes of tTG-DGP complex. The box plot indicates the antibody-binding levels to neoepitopes of tTG-DGP complex; the horizontal line of the box indicates patients with treated but unhealed CeD mucosa. The *red check box* depicts the titers of tTG-IgA.

patients with treated CeD mucosa is necessary. Follow-up biopsy of the duodenum is considered the gold standard of care for treated CeD, although it is both invasive and expensive. Although several serologic tests for CeD are also recommended for monitoring CeD,[27,37–39] the results of these serologic tests are not well correlated with intestinal mucosal healing status in patients with treated CeD.[40,41] A recent meta-analysis reported that serologic tests for CeD, including tests for tTG-IgA and endomysial antibody, have low sensitivity (less than 50%) compared with follow-up biopsy for detecting persistent villous atrophy in patients with CeD who adhere to a GFD, indicating the need for more accurate noninvasive markers for monitoring CeD. Compared with tTG-IgA, DGP-IgA has been shown to be a better predictor of healing status in patients with treated CeD; however, the sensitivity and specificity of DGP-IgA were not optimal in our study. We tested the identified neoepitopes of the tTG-DGP complex to determine whether these neoepitopes predict persistent mucosal damage in patients with treated CeD and found much higher sensitivity and specificity for predicting healing status in patients with treated CeD compared with current serologic tests in our study. In particular, immune reactivity against the neoepitopes of the tTG-DGP complex was still high in patients with treated but unhealed CeD whose tTG-IgA titers were normalized. Thus, these neoepitopes could be good biomarkers for determining healing status in patients with treated CeD mucosa. Immune reactivity against the neoepitopes of the tTG-DGP complex cannot take the place of the necessity of intestinal biopsies when monitoring disease activity because a small portion of patients with CeD can progress to lymphoproliferative disorders or type II refractory CeD, which are associated with aberrant T lymphocytes; however, increased immune reactivity may give clues for ongoing inflammation with persistent intestinal damage. Thus, with such a good positive predictive value (94%) to predict unhealed mucosa, this new test would provide the possibility of avoiding intestinal biopsies if the treated patient still shows the increased immune reactivity against neoepitopes of tTG-DGP complex. Furthermore, because the negative predictive value of the new test (86%) was high, if negative, a need for biopsy in patients with treated CeD may be obviated.

The mechanism that results in persistent immune reactivity against the neoepitopes of the tTG-DGP complex in patients with CeD who are adhering to a GFD and have mucosal atrophy is unclear, especially in patients whose tTG-IgA titers were already normalized. Because persistent intestinal villous atrophy is more commonly associated with poor adherence to a GFD in patients with treated CeD mucosa,[35,42] even a small amount of gluten can maintain the immune response in a person adhering to a GFD. In our

Table 3. Sensitivity, Specificity, and Overall Accuracy of Using tTG-DGP Complex, tTG-IgA, and DGP-IgA to Predict Healing Status in Patients With Treated CeD

Peptide/Protein	Sensitivity % (95% CI)	Specificity % (95% CI)	Overall Accuracy % (95% CI)	PPV	NPV
tTG-DGP complex	84 (74–90)	95 (88–98)	90 (84–94)	0.94	0.86
tTG-IgA[a]	27 (19–38)	93 (85–97)	61 (53–68)	0.78	0.57
DGP-IgA[a]	48 (38–59)	91 (83–95)	70 (63–76)	0.83	0.64

NPV, negative predictive value; PPV, positive predictive value.
[a]Determined using the tTG-IgA or DGP-IgA enzyme-linked immunosorbent assay (Inova Diagnostics, San Diego, CA).

UNCORRECTED PROOF

ARTICLE IN PRESS

study, some treated patients were still positive for tTG-IgA, and, interestingly, these patients showed much higher immune reactivity against neoepitopes of tTG-DGP complex than patients with negative tTG-IgA. Several studies have also demonstrated the persistence of DGP-IgA in patients with CeD who adhered to strict GFD for at least 1 year.[43–46] Furthermore, Spatola et al[45] recently showed that the persistence of antibodies against DGP was associated with nonresponsive CeD in patients with treated CeD, even though the sample size of nonresponsive CeD cases was small. As with other autoimmune diseases,[47–51] epitope spreading may occur in patients with CeD, especially from GPs to tTG. As exposure to the evoking antigens declines in patients with CeD, immunity against self- and non–self-antigens also disappears in a reverse manner. Thus, it is conceivable that immune reactivity against the tTG-DGP complex is highly correlated with mucosal healing in patients with treated CeD mucosa.

Our study has limitations. First, GPs were not deamidated by tTG in a biologic process; rather, these peptides were synthesized using all possible substitutions of specific glutamine residues. Second, we did not determine any experimental 3-dimensional structures of the tTG-DGP complex. However, in this study, the synthesized neoepitopes of the tTG-DGP complex were short (confined to approximately 12 amino acid residues) and mimicked antibody recognition of DGPs and tTG (ie, the antibodies needed to detect only a single patch on the key binding residues).[52,53] Furthermore, the synthesized peptides on the microarray adapted to the 3-dimensional conformational requirements for reactions between antibodies and epitopes.[53] Thus, it is conceivable that the synthesized neoepitopes of the tTG-DGP complex had the specific key binding residues that evoked the immune responses by the antibodies formed in patients with CeD. In addition, patients with treated but unhealed mucosa can be related to gluten exposure so that immune response to exposed gluten may be still persisted in these patients.

In conclusion, the neoepitopes derived from the tTG-DGP complex are extremely accurate predictors of untreated CeD mucosa, and persistent immune response to these epitopes is a promising noninvasive predictor of persistent mucosal injury in patients with treated CeD. These data also suggest that, unlike antibodies to tTG, these antibodies persist long after treatment in patients with CeD with nonhealing mucosa.

Supplementary Material

Note: To access the supplementary material accompanying this article, visit the online version of *Gastroenterology* at www.gastrojournal.org, and at https://doi.org/10.1053/j.gastro.2018.10.025.

References

1. Rubio-Tapia A, Hill ID, Kelly CP, et al. ACG clinical guidelines: diagnosis and management of celiac disease. Am J Gastroenterol 2013;108:656–676; quiz 677.
2. Jabri B, Sollid LM. T Cells in celiac disease. J Immunol 2017;198:3005–3014.
3. Choung RS, Marietta EV, Van Dyke CT, et al. Determination of B-Cell epitopes in patients with celiac disease: peptide microarrays. PLoS One 2016;11:e0147777.
4. Sulkanen S, Halttunen T, Laurila K, et al. Tissue transglutaminase autoantibody enzyme-linked immunosorbent assay in detecting celiac disease. Gastroenterology 1998;115:1322–1328.
5. Walker MM, Murray JA, Ronkainen J, et al. Detection of celiac disease and lymphocytic enteropathy by parallel serology and histopathology in a population-based study. Gastroenterology 2010;139:112–119.
6. Cavell B, Stenhammar L, Ascher H, et al. Increasing incidence of childhood coeliac disease in Sweden. Results of a national study. Acta Paediatr 1992;81:589–592.
7. Ludvigsson JF, Lebwohl B, Green PH. Amount may beat timing: gluten intake and risk of childhood celiac disease. Clin Gastroenterol Hepatol 2016;14:410–412.
8. Myleus A, Ivarsson A, Webb C, et al. Celiac disease revealed in 3% of Swedish 12-year-olds born during an epidemic. J Pediatr Gastroenterol Nutr 2009;49:170–176.
9. Molberg O, McAdam S, Lundin KE, et al. T cells from celiac disease lesions recognize gliadin epitopes deamidated in situ by endogenous tissue transglutaminase. Eur J Immunol 2001;31:1317–1323.
10. Aleanzi M, Demonte AM, Esper C, et al. Celiac disease: antibody recognition against native and selectively deamidated gliadin peptides. Clin Chem 2001;47:2023–2028.
11. Sollid LM, Molberg O, McAdam S, et al. Autoantibodies in coeliac disease: tissue transglutaminase—guilt by association? Gut 1997;41:851–852.
12. Matthias T, Neidhofer S, Pfeiffer S, et al. Novel trends in celiac disease. Cell Mol Immunol 2011;8:121–125.
13. Bizzaro N, Tozzoli R, Villalta D, et al. Cutting-edge issues in celiac disease and in gluten intolerance. Clin Rev Allergy Immunol 2012;42:279–287.
14. Lebwohl B, Murray JA, Rubio-Tapia A, et al. Predictors of persistent villous atrophy in coeliac disease: a population-based study. Aliment Pharmacol Ther 2014; 39:488–495.
15. Breiman L. Random forests. Machine Learning 2001; 45:5–32.
16. Renard BY, Lower M, Kuhne Y, et al. rapmad: robust analysis of peptide microarray data. BMC Bioinformatics 2011;12:324.
17. Pedregosa F, Varoquaux G, Gramfort A, et al. Scikit-learn: machine learning in Python. J Mach Learn Res 2011;12:2825–2830.
18. Hilsenbeck SG, Friedrichs WE, Schiff R, et al. Statistical analysis of array expression data as applied to the problem of tamoxifen resistance. J Natl Cancer Inst 1999;91:453–459.
19. Ciccocioppo R, Di Sabatino A, Ara C, et al. Gliadin and tissue transglutaminase complexes in normal and coeliac duodenal mucosa. Clin Exp Immunol 2003; 134:516–524.
20. van der Windt DA, Jellema P, Mulder CJ, et al. Diagnostic testing for celiac disease among patients with

ARTICLE IN PRESS

abdominal symptoms: a systematic review. JAMA 2010; 303:1738–1746.
21. Health Quality Ontario. Clinical utility of serologic testing for celiac disease in Ontario: an evidence-based analysis. Ont Health Technol Assess Ser 2010;10:1–111.
22. Rashtak S, Ettore MW, Homburger HA, et al. Combination testing for antibodies in the diagnosis of coeliac disease: comparison of multiplex immunoassay and ELISA methods. Aliment Pharmacol Ther 2008;28: 805–813.
23. Sugai E, Selvaggio G, Vazquez H, et al. Tissue transglutaminase antibodies in celiac disease: assessment of a commercial kit. Am J Gastroenterol 2000;95: 2318–2322.
24. Hopper AD, Hadjivassiliou M, Hurlstone DP, et al. What is the role of serologic testing in celiac disease? A prospective, biopsy-confirmed study with economic analysis. Clin Gastroenterol Hepatol 2008;6:314–320.
25. Choung RS, Larson SA, Khaleghi S, et al. Prevalence and morbidity of undiagnosed celiac disease from a community-based study. Gastroenterology 2017;152: 830–839.e5.
26. Husby S, Koletzko S, Korponay-Szabo IR, et al. European Society for Pediatric Gastroenterology, Hepatology, and Nutrition guidelines for the diagnosis of coeliac disease. J Pediatr Gastroenterol Nutr 2012;54:136–160.
27. Ludvigsson JF, Bai JC, Biagi F, et al. Diagnosis and management of adult coeliac disease: guidelines from the British Society of Gastroenterology. Gut 2014; 63:1210–1228.
28. Ludvigsson JF, Agreus L, Ciacci C, et al. Transition from childhood to adulthood in coeliac disease: the Prague consensus report. Gut 2016;65:1242–1251.
29. Skovbjerg H, Koch C, Anthonsen D, et al. Deamidation and cross-linking of gliadin peptides by transglutaminases and the relation to celiac disease. Biochim Biophys Acta 2004;1690:220–230.
30. Matthias T, Pfeiffer S, Selmi C, et al. Diagnostic challenges in celiac disease and the role of the tissue transglutaminase-neo-epitope. Clin Rev Allergy Immunol 2010;38:298–301.
31. Di Pisa M, Pascarella S, Scrima M, et al. Synthetic peptides reproducing tissue transglutaminase-gliadin complex neo-epitopes as probes for antibody detection in celiac disease patients' sera. J Med Chem 2015; 58:1390–1399.
32. Porcelli B, Ferretti F, Vindigni C, et al. Assessment of a test for the screening and diagnosis of celiac disease. J Clin Lab Anal 2016;30:65–70.
33. Lebwohl B, Granath F, Ekbom A, et al. Mucosal healing and risk for lymphoproliferative malignancy in celiac disease: a population-based cohort study. Ann Intern Med 2013;159:169–175.
34. Lebwohl B, Michaelsson K, Green PH, et al. Persistent mucosal damage and risk of fracture in celiac disease. J Clin Endocrinol Metab 2014;99:609–616.
35. Rubio-Tapia A, Rahim MW, See JA, et al. Mucosal recovery and mortality in adults with celiac disease after treatment with a gluten-free diet. Am J Gastroenterol 2010;105:1412–1420.
36. Lebwohl B, Granath F, Ekbom A, et al. Mucosal healing and mortality in coeliac disease. Aliment Pharmacol Ther 2013;37:332–339.
37. Rostom A, Murray JA, Kagnoff MF. American Gastroenterological Association (AGA) Institute technical review on the diagnosis and management of celiac disease. Gastroenterology 2006;131:1981–2002.
38. AGA Institute. AGA Institute medical position statement on the diagnosis and management of celiac disease. Gastroenterology 2006;131:1977–1980.
39. Bai JC, Ciacci C, Corazza GR, et al. World Gastroenterology Organisation practice guidelines: celiac disease. Milwaukee, WI: World Gastroenterology Organisation, 2016:1–35.
40. Leonard MM, Weir DC, DeGroote M, et al. Value of IgA tTG in predicting mucosal recovery in children with celiac disease on a gluten-free diet. J Pediatr Gastroenterol Nutr 2017;64:286–291.
41. **Silvester JA**, **Kurada S**, Szwajcer A, et al. Tests for serum transglutaminase and endomysial antibodies do not detect most patients with celiac disease and persistent villous atrophy on gluten-free diets: a meta-analysis. Gastroenterology 2017;153:689–701.e1.
42. Lanzini A, Lanzarotto F, Villanacci V, et al. Complete recovery of intestinal mucosa occurs very rarely in adult coeliac patients despite adherence to gluten-free diet. Aliment Pharmacol Ther 2009;29:1299–1308.
43. Kaukinen K, Collin P, Laurila K, et al. Resurrection of gliadin antibodies in coeliac disease. Deamidated gliadin peptide antibody test provides additional diagnostic benefit. Scand J Gastroenterol 2007;42:1428–1433.
44. Volta U, Granito A, Fiorini E, et al. Usefulness of antibodies to deamidated gliadin peptides in celiac disease diagnosis and follow-up. Dig Dis Sci 2008;53: 1582–1588.
45. Spatola BN, Kaukinen K, Collin P, et al. Persistence of elevated deamidated gliadin peptide antibodies on a gluten-free diet indicates nonresponsive coeliac disease. Aliment Pharmacol Ther 2014;39:407–417.
46. Monzani A, Rapa A, Fonio P, et al. Use of deamidated gliadin peptide antibodies to monitor diet compliance in childhood celiac disease. J Pediatr Gastroenterol Nutr 2011;53:55–60.
47. McRae BL, Vanderlugt CL, Dal Canto MC, et al. Functional evidence for epitope spreading in the relapsing pathology of experimental autoimmune encephalomyelitis. J Exp Med 1995;182:75–85.
48. Lehmann PV, Forsthuber T, Miller A, et al. Spreading of T-cell autoimmunity to cryptic determinants of an autoantigen. Nature 1992;358:155–157.
49. Sohnlein P, Muller M, Syren K, et al. Epitope spreading and a varying but not disease-specific GAD65 antibody response in Type I diabetes. The Childhood Diabetes in Finland Study Group. Diabetologia 2000;43:210–217.
50. Vincent A, Willcox N, Hill M, et al. Determinant spreading and immune responses to acetylcholine receptors in myasthenia gravis. Immunol Rev 1998;164:157–168.
51. Vanderlugt CL, Miller SD. Epitope spreading in immune-mediated diseases: implications for immunotherapy. Nat Rev Immunol 2002;2:85–95.

CLINICAL AT
UNCORRECTED PROOF

ARTICLE IN PRESS

52. Sivalingam GN, Shepherd AJ. An analysis of B-cell epitope discontinuity. Mol Immunol 2012;51:304–309.
53. Forsstrom B, Axnas BB, Stengele KP, et al. Proteome-wide epitope mapping of antibodies using ultra-dense peptide arrays. Mol Cell Proteomics 2014;13:1585–1597.

Author names in bold designate shared co-first authorship.

Received April 25, 2018. Accepted October 9, 2018.

Reprint requests
Address requests for reprints to: Joseph A. Murray, MD, Mayo Clinic, 200 First Street, SW, Rochester, Minnesota 55905. e-mail: murray.joseph@mayo.edu; fax: 507–255–6318.

Acknowledgments
The authors thank Linda H. Michalowski for her assistance in the preparation of the manuscript.

Author contributions: Study Concept and Design: Rok Seon Choung, Vasanth Jayaraman, and Joseph A. Murray. Analysis and Interpretation of Data, Drafting of the Manuscript, and Critical Revision of the Manuscript for Important Intellectual Content: Rok Seon Choung, Eric V. Marietta, Vasanth Jayaraman, Karthik Krishna, and Joseph A. Murray. Administrative, Technical, or Material Support: Shahryar Khaleghi Rostamkolaei, Josephine M. Ju, Carol T. Van Dyke, J. J. Rajasekaran, Tianhao Wang, Kang Bei, Karthik Krishna, and Hari Krishnan Krishnamurthy. Study Supervision: Joseph A. Murray.

Conflicts of interest
Joseph A. Murray has received grant support from the National Institutes of Health and Alba Therapeutics and receives ongoing support from the Broad Medical Research Program at Crohn's and Colitis Foundation. He serves on the advisory board of Celimmune, LLC; was a consultant to AMAG Pharmaceuticals, Entera Health, Inc., Sonomaceuticals, LLC, BioLineRx, GlaxoSmithKline, Genentech, Inc., and Glenmark Pharmaceuticals Ltd.; serves as a consultant to Boehringer Ingelheim; and has equity options in Torax Medical. The remaining authors have no conflicts to disclose. J. J. Rajasekaran, Vasanth Jayaraman, Kang Bei, Hari Krishnamurthy, Tianhao Wang, Karenah E. Rajasekaran, Karthik Krishna, and Hari Krishnan Krishnamurthy are employed by Vibrant Sciences. The content is solely the responsibility of the authors and does not necessarily represent the official view of the National Institutes of Health.

UNCORRECTED PROOF

ARTICLE IN PRESS

Supplementary Table 1. Clinical Characteristics of the Exploratory Population

Group	N	Age, y		Sex, %	
		Mean	Range	Male	Female
Celiac disease	90	39.4	19.5–60.2	43	57
Healthy controls	79	40.2	19.7–63.3	48	52

Supplementary Table 2. Clinical Characteristics of the Validation Population

Group	n	Age, y		Sex, %	
		Mean	Range	Male	Female
Celiac disease	82	47.7	34.0–59.0	28.0	72.0
Healthy controls	217	35.6	26.6–44.6	40.1	59.9

Supplementary Table 3. List of tTG–DGP Complex Sequences Showing High Sensitivity and Specificity for Identifying CeD in Healthy Control Patients With Area Under the Curve > 0.7

FEDGILEQPPEQ, PFPQKTVEIPEQ, FPLRDAPEQQPE, FPQQPFWLTEQP, FDVFAHPFPFPQ, AWCPADFPEEQP, FPEPAPSQEQPF, AEVSLQEQPPEQ, EMIWNFPFPEQP, EQPPEQAEVSLQ, FPEQPEYGDGVS, PFPPEQALLVEP, HDQNSNQPFQPE, PFPSVDILRQPE, EQPLTQQGFEQP, FPEFPEVVNFES, QPFQPEYNSAHD, DLCREKPEQEQP, EKLVVRPEQQPE, FPQPGYEGWEQP, QPEQPEYQGSSF, PFPNRSLIVQPF, DCTLSLPEQQPE, PFPSVDSLTFPE, DAVEEGQPEPEQ, ASTGYQQPEPFP, FEGRNYFPEFPQ, EQPLQNPLPQPF, GWQALDFPQPFP, PEQRKLVAEFPE, QPEPVPVRAFPQ, PFPQPFVFAEVN, QPFLAERDLFPE, PEQPEQVDQQDC, EQPSGMVNCEQP, FPELCARTVPFP, PFPLLFNAWPFP, HLNKLAPEQQPE, EQPNAPIGLPFP, FPEREAFTREQP, FPQPFPAAVACT, QPFPEQYCCGPV, EQPQSMNMGPFP, CRLLLCPEQPEQ, IPTRVVFPEEQP, QPFLHMGLHQPE, PFPLSLEASQPE, FPQNGRDHHQPF, QPENNTAEEFPE, PFPLDPTPQQPF, AHITNNEQPEQP, FPQKVRMDLQPF, FPEMGSDFDQPF, PEQKSVGRDQPE, IKVRALPFPPEQ, FPENFHCWVPEQ, GRVVSGFPQQPF, QPEPFPASTGYQ, AAVACTFPQPFP, PFPPEQWMTRPD, PEQEQPWVESWM, QPEPVYVGRFPE, PEQNYEASVQPF, EQPQPFVVDWIQ, QPEQPEYPEGSS, PFPPKQKRKQPF, QPFNFGQFEEQP, QPEQPFVNADVV, ALLVEPPFPPEQ, EGDLSTQPFQPF, PEQNCNDDQQPF, PFPTRANHLPEQ, DQGVLLPEQQPE, GPECGTFPQQPF, FPQLVLERCQPF, QPFEQPVVTNYN, GLYRLSQPFEQP, ADAVYLPEQQPF, FPQSEGTYCQPE, FPQSNLLIEPEQ, ENPEIKFPQPFP, QPFQEYVLTFPQ, QPFSWIGSVFPQ, EDITHTEQPQPF, CQRVKYQPEPEQ, EIPDPVFPQQPE, EGAGLTQPEPEQ, QPESFVLGHPEQ, PEQKNHGCQEQP, PFPPQEKSEEQP, QPFPVEAGEFPE, EQPMAEELVFPE, IKIRILPFPPEQ, ILDICLPFPFPQ, FPELTLHFEFPE, DLYLENQPFPEQ, HTYKYPPFPFPQ, EQPFPEVIIGPA, DGSVHKFPEPFP, FPQLEGCTFFPE, QPERCDLELQPF, QPETKARFPQPE, FPQRNEFGEFPE, CWVFAAFPQQPE, FPELAEKEEQPE, QPFPFPWDNNYG, FPQRRSSPVFPE, ESNLIKPEQQPF, DLLPLHEQPFPE, DCLTESQPFPEQ, GHFILLPEQQPE, FSEKSVFPEQPE, QPEEQPTVSYNG, GEEVKVPEQPEQ, EPVINSQPEPEQ, EEERQEEQPQPF, HHTADLQPEQPE, GTKYLLPFPFPE, EQPTFTVEGPFP, GEIQGDQPEQPF, PFPLPVALEFPE, CILYEKEQPFPE, QPFPKFLKNQPE, FPQLTFSVVPEQ, PFPEQPVVTGPA, EKYRDCFPEPEQ, PFPTATVVDQPE, PFPLDVNPKQPF, FPQQGSAKFQPE, PFPRDEREDQPF, EQPEQPVRRGQP, PFPSVPLCIQPE, ILGEPKQPFQPE, FPQPFPVSPMSW, QPELHKLVVQPE, GFIYQGFPQPFP, EQPEQPAHITNN, EEYVCRFPEPFP, PEQPDLQPGQPE, QPFFPQTTPANA, EQPLTEEQKQPE, ESDKLKQPFPEQ, EQPNGILGPEQP, PFPQEAGTKFPQ, EETGMAPFPEQP, PFPMAMRIRQPF, QPELLGRWDQPE, DAPFVFQPFQPF, IEYFRNEQPFPE, QPESTKYDAQPF, CLILLDQPEPFP, FPERCLGIPEQP, EQPNIPWNFPFP, GDKSEMPEQFPE, PFPFPQYLDSEE, FPENSYLLAPEQ, EQPRAIKEGQPF, CTVLRCFPQEQP, PEQKYGQCWFPQ, EGDWTAPEQEQP, PEQQPFADAVYL, PFPLKAVKGEQP, EQPSSEEREPFP, EQPRDCSRRPEQ, EQPNVIIGPFPE, PEQLLNLNLPEQ, EQPSLQLTTFPE, PEQNLEPFSQPF, HKSINRFPEEQP, EQPLRRWKNPEQ, PFPKNAGRDEQP, ELETNGPFPQPF